To assess if PF-04958242 can attenuate the ketamine-induced cognitive impairment in verbal learning and memory, episodic memory and spatial working memory in healthy volunteers.
This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
29
PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
Placebo capsule orally administered on Days 1 - 5
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
West Haven, Connecticut, United States
Test score on the Hopkins Verbal Learning Test - Immediate Recall
Time frame: Day 5
Test score on the Weschler Digit Span Test
Time frame: Day 5
Test score on the CogState N-back test
Time frame: Day 5
Test score on the CogState Spatial Working memory test
Time frame: Day 5
Test score on the CogState One Card Learning test
Time frame: Day 5
Test score on the Hopkins Verbal Learning test - Delayed Recall
Time frame: Day 5
Retrospective rating on the Positive and Negative Syndrome Scale -modified scale'
Time frame: Day 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.